Viewing Study NCT03873493

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:02 AM
Ignite Modification Date: 2026-02-26 @ 2:18 AM
Study NCT ID: NCT03873493
Status: COMPLETED
Last Update Posted: 2022-12-19
First Post: 2019-03-12
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Leukemia View
None T-cell Prolymphocytic Leukemia (T-PLL) View
None Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None T-cell Prolymphocytic Leukemia (T-PLL) View
None Cancer View
None Venetoclax View
None Venclexta View
None Venclyxto View
None Ibrutinib View
None Imbruvica View
None Relapsed or Refractory T-lymphoid malignancy View